Authors
Lisha Wu, Zhengxiong Tao, Gan Wang, Yaling Chen, Zheng Sun, Shuang Lu
Published in
Cellular and molecular gastroenterology and hepatology. Pages 101929. Nov 14, 2026. Epub Nov 14, 2026.
Abstract
The beneficial effects of prebiotics are conventionally attributed to their fermentation by the gut microbiota. Here, we uncover a direct, microbiota-independent mechanism by which mannuronate oligosaccharides (MAOS) fortify the mucus barrier in a structure-dependent manner. We demonstrate that MAOS functions as a direct host agonist by binding the NLRP6 pyrin domain at Arg87 with high affinity (KD = 0.9 μM). This binding event triggers NLRP6 inflammasome assembly and subsequent caspase-1 activation, leading to the formation of non-lytic GSDMD pores specifically at the apical membrane of goblet cells. These pores facilitate mucin 2 (Muc2) secretion, thereby enhancing mucosal defense and limiting bacterial adhesion. Our findings establish MAOS as a novel class of NLRP6 agonist that enhances mucosal barrier function through a GSDMD-dependent secretory mechanism. This work highlights that specific glycan structures, rather than microbial fermentation, can directly engage host immune receptors. This opens a new avenue for developing structure-guided glycan-based therapeutics that act directly on the host immune system to treat inflammatory bowel disease (IBD) and other mucus barrier disorders.
PMID:
43033869
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0